OSIMERTINIB AS FIRST-LINE AND SECOND-LINE THERAPY FOR EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN CHINA
第一作者机构：[1]Sichuan Cancer Hospital & Institute, Chengdu, China
通讯作者：
推荐引用方式(GB/T 7714)：
Zhou J.,Jiang G..OSIMERTINIB AS FIRST-LINE AND SECOND-LINE THERAPY FOR EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN CHINA[J].VALUE IN HEALTH.2020,23:S54-S54.doi:10.1016/j.jval.2020.04.1658.
APA：
Zhou, J.&Jiang, G..(2020).OSIMERTINIB AS FIRST-LINE AND SECOND-LINE THERAPY FOR EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN CHINA.VALUE IN HEALTH,23,
MLA：
Zhou, J.,et al."OSIMERTINIB AS FIRST-LINE AND SECOND-LINE THERAPY FOR EGFR MUTATION-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER: A COST-EFFECTIVENESS ANALYSIS IN CHINA".VALUE IN HEALTH 23.(2020):S54-S54
医学